Advisory Board Member

Dr Björn Carlsson

Björn joined the NDA in October 2020, he is an expert in non-clinical development for all types of pharmaceuticals and all types of indications.  As a highly experienced non- clinical assessor his strategic & scientific expertise is essential for the successful development of new medicinal products.

He is also an associate professor in industrial experimental clinical immunology at Uppsala University.

Key Areas Of Expertise
  • Extensive expertise in the inner workings of the EU regulatory systems
  • Advanced Therapies (cell, gene therapies and tissue engineering)
  • Non-clinical development for all types of pharmaceuticals in all types of indications.
    • Preformed 100+ scientific advices (national and centralized)
    • Non-clinical assessor for 20+ MAAs (SE acting as Rapporteur)
    • Principal non-clinical assessor for multiple CAT ATMP certifications
    • Horizon 2020 application evaluator 2016-2019
  • Professional presentation skills and extensive teaching experience
    • Associate professor in industrial experimental clinical immunology at Uppsala University
Before NDA

Björn spent 12 years at the Swedish Medicines Agency (MPA) primarily as a non-clinical assessor. He was also the Swedish alternate delegate to the committee for advanced therapy (CAT) at the European Medicines Agency (EMA).
Between 2016-2019 Björn was an Horizon 2020 evaluator for the European Commission.

Recent Publications

Berglund D., Karlsson M., Biglarnia A-R., Lorant T., Tufveson G., Korsgren O. and Carlsson B. Obtaining regulatory T cells from uremic patients awaiting kidney transplantation - for the use in clinical trials. Clin Exp Immunol. 2013 Aug;173(2):310-22.

Rashkova V., Nilsson B., Carlsson B., Eriksson F. and Essand M. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLAA2+ prostate and breast cancer cells. Proc Natl Acad Sci U S A., 25;109(39):15877-81, 2012.

Ulenhag GJ., Sadeghi AM., Carlsson B., Ahlström H., Mosavi F., Wagenius G. and Tötterman TH. Adoptive T cell therapy for malignant melanoma patients with TILs obtained by ultrasoundguided needle biopsy. Cancer immunology Immunotherapy, 61(5):725-32, 2012

Carlsson B., Cheng WS., Tötterman TH. and Essand M. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br. J. Haematology, 121: 428-438, 2003

Dr Björn Carlsson

LinkedIn

Stay up to date

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World